The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Jekyll and Hyde: the role of the microenvironment on the progression of cancer
Open accessAbstract
It is now recognized that the host microenvironment undergoes extensive change during the evolution and progression of cancer. This involves the generation of cancer‐associated fibroblasts (CAFs), which, through release of growth factors and cytokines, lead to enhanced angiogenesis, increased tumour growth and invasion. It has also been demonstrated that CAFs may modulate the cancer stem cell (CSC) phenotype, which has therapeutic implications. The altered fibroblast phenotype also contributes to the development of an altered extracellular matrix (ECM), with synthesis of ECM isoforms rarely found in normal tissues, including tenascin‐C isoforms and the fibronectin EDA isoform. There is also emerging evidence of how the tensile strength of the tumour‐associated ECM may be modified and lead to altered signalling in tumour cells. The hypoxic environment of the tumour stimulates angiogenesis and also impacts on other aspects of cell signalling, including the c‐met pathway and lysyl oxidase‐mediated signalling, which can directly promote tumour cell invasion. The inflammatory infiltrate associated with many solid tumours also modulates tumour function, having both anti‐ and pro‐tumour effects. All of these components of the microenvironment provide potential targets for therapeutic attack, with a number of molecules already in clinical trials. It is also becoming evident that characterizing the tumour microenvironment can provide important prognostic and predictive information about tumours, independent of the tumour cell phenotype. Copyright © 2010 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Lysyl oxidase is essential for hypoxia-induced metastasis
Erler, J. T., Bennewith, K. L., Nicolau, M., Dornhöfer, N., Kong, C., Le, Q.-T., Chi, J.-T. A., Jeffrey, S. S., & Giaccia, A. J. (2006) · Nature · doi:10.1038/nature04695 · Cited by 1,309
RetractedMatrix elasticity directs stem cell lineage specification
Engler, A. J., Sen, S., Sweeney, H. L., & Discher, D. E. (2006) · Cell · doi:10.1016/j.cell.2006.06.044 · Cited by 13,915
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Exploring the full spectrum of macrophage activation
Mosser, D. M., & Edwards, J. P. (2008) · Nature Reviews Immunology · doi:10.1038/nri2448 · Cited by 9,144
Alternative activation of macrophages
Gordon, S. (2003) · Nature Reviews Immunology · doi:10.1038/nri978 · Cited by 6,189
New functions for the matrix metalloproteinases in cancer progression
Egeblad, M., & Werb, Z. (2002) · Nature Reviews Cancer · doi:10.1038/nrc745 · Cited by 6,108
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
Kalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538
Orimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Cited by
Bochet, L., Lehuédé, C., Dauvillier, S., Wang, Y. Y., Dirat, B., Laurent, V., Dray, C., Guiet, R., Maridonneau-Parini, I., Le Gonidec, S., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0530 · Cited by 529
Edin, S., Wikberg, M. L., Dahlin, A. M., Rutegård, J., Öberg, Å., Oldenborg, P.-A., & Palmqvist, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047045 · Cited by 454
Metal Drugs and the Anticancer Immune Response
Englinger, B., Pirker, C., Heffeter, P., Terenzi, A., Kowol, C. R., Keppler, B. K., & Berger, W. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00396 · Cited by 355
The immune system and cancer evasion strategies: therapeutic concepts
Muenst, S., Läubli, H., Soysal, S. D., Zippelius, A., Tzankov, A., & Hoeller, S. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12470 · Cited by 304
Tumour-on-a-chip: microfluidic models of tumour morphology, growth and microenvironment
Tsai, H.-F., Trubelja, A., Shen, A. Q., & Bao, G. (2017) · Journal of The Royal Society Interface · doi:10.1098/rsif.2017.0137 · Cited by 214
Lochhead, P., Chan, A. T., Nishihara, R., Fuchs, C. S., Beck, A. H., Giovannucci, E., & Ogino, S. (2015) · Modern Pathology · doi:10.1038/modpathol.2014.81 · Cited by 206
Dumont, N., Liu, B., DeFilippis, R. A., Chang, H., Rabban, J. T., Karnezis, A. N., Tjoe, J. A., Marx, J., Parvin, B., & Tlsty, T. D. (2013) · Neoplasia · doi:10.1593/neo.121950 · Cited by 192
Cai, J., Tang, H., Xu, L., Wang, X., Yang, C., Ruan, S., Guo, J., Hu, S., & Wang, Z. (2012) · Carcinogenesis · doi:10.1093/carcin/bgr230 · Cited by 173
3D Bioprinting of Tumor Models for Cancer Research
Kang, Y., Datta, P., Shanmughapriya, S., & Ozbolat, I. T. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c00791 · Cited by 112
Platel, V., Faure, S., Corre, I., & Clere, N. (2019) · Journal of Oncology · doi:10.1155/2019/8361945 · Cited by 101
Stretching Fibroblasts Remodels Fibronectin and Alters Cancer Cell Migration
Ao, M., Brewer, B. M., Yang, L., Franco Coronel, O. E., Hayward, S. W., Webb, D. J., & Li, D. (2015) · Scientific Reports · doi:10.1038/srep08334 · Cited by 96
Contois, L. W., Nugent, D. P., Caron, J. M., Cretu, A., Tweedie, E., Akalu, A., Liebes, L., Friesel, R., Rosen, C., Vary, C., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.267732 · Cited by 46
Metadata
- Authors
- Allen, M., & Louise Jones, J.
- Venue
- The Journal of Pathology
- Publisher
- Wiley
- Published
- 2010-10-29
- Volume
- 223
- Issue
- 2
- Pages
- 163-177
- ISSN
- 0022-3417 (ISSN-L)
- 1096-9896
- OpenAlex
- W2025199554
- Cited by
- 375
- References
- 26
- FWCI
- 19.66
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
